Your browser doesn't support javascript.
loading
Cardiac troponin and COVID-19 severity: Results from BIOCOVID study.
García de Guadiana-Romualdo, Luis; Morell-García, Daniel; Rodríguez-Fraga, Olaia; Morales-Indiano, Cristian; María Lourdes Padilla Jiménez, Ana; Gutiérrez Revilla, José Ignacio; Urrechaga, Eloísa; Álamo, José María; Hernando Holgado, Ana María; Lorenzo-Lozano, María Del Carmen; Sánchez Fdez-Pacheco, Silvia; de la Hera Cagigal, Patricia; Juncos Tobarra, María Ángeles; Vílchez, Juan A; Vírseda Chamorro, Isabel; Gutiérrez Garcia, Irene; Pastor Murcia, Yolanda; Sahuquillo Frías, Laura; Altimira Queral, Laura; Nuez-Zaragoza, Elisa; Adell Ruiz de León, Juan; Ruiz Ripa, Alicia; Salas Gómez-Pablos, Paloma; Cebreiros López, Iria; Fernández Uriarte, Amaia; Larruzea, Álex; López Yepes, María Luisa; Sancho-Rodríguez, Natalia; Zamorano Andrés, María Consuelo; Pedregosa Díaz, José; Acevedo Alcaraz, Cristina; Blázquez Manzanera, Alfonso-L; Pérez Sanmartín, Sonia; Baamonde Calzada, María Del Carmen; Vera, Marina; Valera Nuñez, Elena; Canalda Campás, Magdalena; García Muñoz, Sara; Bauça, Josep Miquel; Vicente Gutiérrez, Luis; Jiménez Añón, Laura; Pérez Martínez, Alfonso; Pons Castillo, Aurelio; González Tamayo, Ruth; Férriz Vivancos, Jorge; José Alcaide Martín, María; Ferrer Díaz de Brito Fernández, Vicente; Aguadero, Vicente; García Arévalo, María Gloria; Arnaldos Carrillo, María.
Afiliación
  • García de Guadiana-Romualdo L; Laboratory Medicine Department, Hospital Universitario Santa Lucía, Cartagena, Spain.
  • Morell-García D; Laboratory Medicine Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
  • Rodríguez-Fraga O; Laboratory Medicine Department, Hospital Universitario La Paz, Madrid, Spain.
  • Morales-Indiano C; Laboratory Medicine Department, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.
  • María Lourdes Padilla Jiménez A; Laboratory Medicine Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Gutiérrez Revilla JI; Department of Clinical Biochemistry, Hospital Sierrallana, Torrelavega, Spain.
  • Urrechaga E; Biocruces Bizkaia Health Research Institute, Baracaldo, Spain.
  • Álamo JM; Biochemical Laboratory, Hospital Marina Baixa, Villajoyosa, Spain.
  • Hernando Holgado AM; Laboratory Medicine Department, Hospital Universitario Vinalopó, Elche, Alicante, Spain.
  • Lorenzo-Lozano MDC; Laboratory Medicine Department, Complejo Hospitalario de Toledo, Toledo, Spain.
  • Sánchez Fdez-Pacheco S; Laboratory Medicine Department, Hospital Central de la Defensa Gómez Ulla, Madrid, Spain.
  • de la Hera Cagigal P; Laboratory Medicine Department, Hospital Universitario de Basurto, Bilbao, Spain.
  • Juncos Tobarra MÁ; Laboratory Medicine Department, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
  • Vílchez JA; Laboratory Medicine Department, Hospital Universitario Morales Meseguer, Murcia, Spain.
  • Vírseda Chamorro I; Laboratory Medicine Department, Hospital Arnau de Vilanova, Valencia, Spain.
  • Gutiérrez Garcia I; Laboratory Medicine Department, Hospital Universitario de Torrevieja, Torrevieja, Spain.
  • Pastor Murcia Y; Laboratory Medicine Department, Consorci Hospital General Universitari de València, Valencia, Spain.
  • Sahuquillo Frías L; Laboratory Medicine Department, Hospital Can Misses, Ibiza, Spain.
  • Altimira Queral L; Laboratory Medicine Department, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Spain.
  • Nuez-Zaragoza E; Laboratory Medicine Department, Consorci Corporació Sanitària Parc Tauli, Sabadell, Barcelona, Spain.
  • Adell Ruiz de León J; Laboratory Medicine Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
  • Ruiz Ripa A; Laboratory Medicine Department, Hospital de Mataró, Mataró, Barcelona, Spain.
  • Salas Gómez-Pablos P; Catlab, Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain.
  • Cebreiros López I; Laboratory Medicine Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
  • Fernández Uriarte A; Catlab, Hospital Universitario Mútua Terrassa, Barcelona, Spain.
  • Larruzea Á; Laboratory Medicine Department, Hospital Fundació Sanitària Mollet, Barcelona, Spain.
  • López Yepes ML; Laboratory Medicine Department, Hospital Virgen del Castillo, Yecla, Spain.
  • Sancho-Rodríguez N; Laboratory Medicine Department, Hospital General Universitario Reina Sofía, Murcia, Spain.
  • Zamorano Andrés MC; Laboratory Medicine Department, Hospital de la Vega Lorenzo Guirao, Cieza, Spain.
  • Pedregosa Díaz J; Laboratory Medicine Department, Hospital Verge de la Cinta, Tortosa, Spain.
  • Acevedo Alcaraz C; Laboratory Medicine Department, Hospital Universitario Los Arcos del Mar Menor, San Javier, Spain.
  • Blázquez Manzanera AL; Laboratory Medicine Department, Hospital General Universitario Rafael Méndez, Lorca, Spain.
  • Pérez Sanmartín S; Laboratory Medicine Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Baamonde Calzada MDC; Department of Clinical Biochemistry, Hospital Sierrallana, Torrelavega, Spain.
  • Vera M; Biochemical Laboratory, Hospital Marina Baixa, Villajoyosa, Spain.
  • Valera Nuñez E; Laboratory Medicine Department, Complejo Hospitalario de Toledo, Toledo, Spain.
  • Canalda Campás M; Laboratory Medicine Department, Hospital Central de la Defensa Gómez Ulla, Madrid, Spain.
  • García Muñoz S; Laboratory Medicine Department, Hospital Universitario de Basurto, Bilbao, Spain.
  • Bauça JM; Laboratory Medicine Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
  • Vicente Gutiérrez L; Laboratory Medicine Department, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.
  • Jiménez Añón L; Laboratory Medicine Department, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain.
  • Pérez Martínez A; Laboratory Medicine Department, Hospital Universitario Morales Meseguer, Murcia, Spain.
  • Pons Castillo A; Laboratory Medicine Department, Hospital Arnau de Vilanova, Valencia, Spain.
  • González Tamayo R; Laboratory Medicine Department, Hospital Universitario de Torrevieja, Torrevieja, Spain.
  • Férriz Vivancos J; Laboratory Medicine Department, Consorci Hospital General Universitari de València, Valencia, Spain.
  • José Alcaide Martín M; Laboratory Medicine Department, Hospital Universitario La Paz, Madrid, Spain.
  • Ferrer Díaz de Brito Fernández V; Internal Medicine Department, Sant Boi de Llobregat, Barcelona, Spain.
  • Aguadero V; Laboratory Medicine Department, Consorci Corporació Sanitària Parc Tauli, Sabadell, Barcelona, Spain.
  • García Arévalo MG; Laboratory Medicine Department, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
  • Arnaldos Carrillo M; Laboratory Medicine Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Eur J Clin Invest ; 51(6): e13532, 2021 Jun.
Article en En | MEDLINE | ID: mdl-33660278
BACKGROUND: Myocardial injury is a common finding in COVID-19 strongly associated with severity. We analysed the prevalence and prognostic utility of myocardial injury, characterized by elevated cardiac troponin, in a large population of COVID-19 patients, and further evaluated separately the role of troponin T and I. METHODS: This is a multicentre, retrospective observational study enrolling patients with laboratory-confirmed COVID-19 who were hospitalized in 32 Spanish hospitals. Elevated troponin levels were defined as values above the sex-specific 99th percentile upper reference limit, as recommended by international guidelines. Thirty-day mortality was defined as endpoint. RESULTS: A total of 1280 COVID-19 patients were included in this study, of whom 187 (14.6%) died during the hospitalization. Using a nonspecific sex cut-off, elevated troponin levels were found in 344 patients (26.9%), increasing to 384 (30.0%) when a sex-specific cut-off was used. This prevalence was significantly higher (42.9% vs 21.9%; P < .001) in patients in whom troponin T was measured in comparison with troponin I. Sex-specific elevated troponin levels were significantly associated with 30-day mortality, with adjusted odds ratios (ORs) of 3.00 for total population, 3.20 for cardiac troponin T and 3.69 for cardiac troponin I. CONCLUSION: In this multicentre study, myocardial injury was a common finding in COVID-19 patients. Its prevalence increased when a sex-specific cut-off and cardiac troponin T were used. Elevated troponin was an independent predictor of 30-day mortality, irrespective of cardiac troponin assay and cut-offs to detect myocardial injury. Hence, the early measurement of cardiac troponin may be useful for risk stratification in COVID-19.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mortalidad / Troponina I / Troponina T / COVID-19 / Cardiomiopatías Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Clin Invest Año: 2021 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Mortalidad / Troponina I / Troponina T / COVID-19 / Cardiomiopatías Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Eur J Clin Invest Año: 2021 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido